Synthetic strategies and chemical and structural aspects of the synthesis of HPMA
copolymer conjugates with various drugs and other biologically active molecules are …

The design, synthesis and properties of N-(2-hydroxypropyl) methacrylamide (HPMA)
copolymers as carriers of anticancer drugs are reviewed. Macromolecular therapeutics …

Improved therapies for the treatment of life-threatening and chronic debilitating disease are
urgently needed. Many seek to achieve more effective chemotherapy through the use of …

Over the past few decades, numerous polymer drug carrier systems are designed and
synthesized, and their properties are evaluated. Many of these systems are based on water …

The overview covers the discovery of N-(2-hydroxypropyl) methacrylamide (HPMA)
copolymers, initial studies on their synthesis, evaluation of biological properties, and …

N-(2-Hydroxypropyl) methacrylamide (HPMA) copolymer conjugates containing doxorubicin
designed in the late 1970s/early 1980s as anticancer polymer therapeutics were the first …

Data on the synthesis, physicochemical characterisation and in vitro and in vivo biological
properties of the new, nontargeted or antibody-targeted polymer–doxorubicin conjugates …

This paper summarizes recent work on the design and development of targeted polymeric
bioconjugates based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers …

Poly [N‐(2‐hydroxypropyl) methacrylamide](HPMA) was one of the first polymers applied as
polymer drug conjugate in the clinics. Since then many attempts have been made to expand …

The field of polymer therapeutics has evolved over the past decade and has resulted in the
development of polymer–drug conjugates with a wide variety of architectures and chemical …